110 related articles for article (PubMed ID: 32860075)
1. Risk of relapse after anti-PD1 discontinuation in patients with Hodgkin lymphoma.
Manson G; Brice P; Herbaux C; Silva MG; Bouabdallah K; Deau B; Bouteloup J; Schiano JM; Nicolas-Virelizier E; Maerevoet M; Ghesquieres H; Stamatoullas A; Antier C; Carlo-Stella C; de Charette M; Poizeau F; Dercle L; Houot R
Eur J Nucl Med Mol Imaging; 2021 Apr; 48(4):1144-1153. PubMed ID: 32860075
[TBL] [Abstract][Full Text] [Related]
2. Discontinuation of anti-PD1 in advanced melanoma: an observational retrospective study from the Italian Melanoma Intergroup.
Rubatto M; Fava P; Stanganelli I; Ribero S; Pigozzo J; Di Giacomo AM; Ridolfi L; Tronconi MC; Trojaniello C; Bersanelli M; Garutti M; Indini A; De Risi I; De Tursi M; Merelli B; Morgese F; Occelli M; Cappellini GCA; Poletto S; Fedele D; Brugnara S; Frisinghelli M; Formisano L; Conca R; Tucci M; Russillo M; Ceroni L; Queirolo P; Targato G; Strippoli S; Mandalà M; Guida M; Quaglino P
Eur J Cancer; 2023 Jul; 187():25-35. PubMed ID: 37099946
[TBL] [Abstract][Full Text] [Related]
3. Long-term efficacy of anti-PD1 therapy in Hodgkin lymphoma with and without allogenic stem cell transplantation.
Manson G; Mear JB; Herbaux C; Schiano JM; Casasnovas O; Stamatoullas A; Deau B; Schmitt A; Garnier G; Regny C; Bouabdallah K; Moles-Moreau MP; Ghesquieres H; Tempescul A; Dulery R; Nicolas-Virelizier E; Delmer A; Borel C; Chauchet A; Damotte D; Dercle L; Brice P; Houot R;
Eur J Cancer; 2019 Jul; 115():47-56. PubMed ID: 31082693
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of chemotherapy after anti-PD-1 blockade failure for relapsed and refractory Hodgkin lymphoma.
Casadei B; Argnani L; Morigi A; Lolli G; Broccoli A; Pellegrini C; Nanni L; Stefoni V; Coppola PE; Carella M; Cavo M; Zinzani PL
Cancer Med; 2020 Nov; 9(21):7830-7836. PubMed ID: 32881376
[TBL] [Abstract][Full Text] [Related]
5. Real-World Experience of PD-1 Inhibitors for Relapsed and Refractory Hodgkin Lymphoma: A Multicenter Retrospective Analysis of Patients in China.
Yu W; Geng M; Hao J; Yan Z; Mi JQ
Acta Haematol; 2023; 146(4):307-315. PubMed ID: 37023729
[TBL] [Abstract][Full Text] [Related]
6. Outcomes Related to FDG-PET-CT Response in Patients With Hodgkin Lymphoma Treated With Brentuximab-Vedotin at Relapse or Consolidation.
Kedmi M; Khaustov P; Ribakovsy E; Benjamini O; Avigdor A
Clin Lymphoma Myeloma Leuk; 2021 Dec; 21(12):e929-e937. PubMed ID: 34366266
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors and long-term outcome of autologous haematopoietic stem cell transplantation following a uniform-modified BEAM-conditioning regimen for patients with refractory or relapsed Hodgkin lymphoma: a single-center experience.
Czyz A; Lojko-Dankowska A; Dytfeld D; Nowicki A; Gil L; Matuszak M; Kozlowska-Skrzypczak M; Kazmierczak M; Bembnista E; Komarnicki M
Med Oncol; 2013; 30(3):611. PubMed ID: 23702734
[TBL] [Abstract][Full Text] [Related]
8. Sustainable responses in metastatic melanoma patients with and without brain metastases after elective discontinuation of anti-PD1-based immunotherapy due to complete response.
Dimitriou F; Zaremba A; Allayous C; Kähler KC; Gerard CL; Festino L; Schäfer S; Toussaint F; Heinzerling L; Hassel JC; Ascierto PA; Michielin O; Hauschild A; Lebbe C; Livingstone E; Ramelyte E; Cheng PF; Dummer R; Mangana J
Eur J Cancer; 2021 May; 149():37-48. PubMed ID: 33823361
[TBL] [Abstract][Full Text] [Related]
9. Checkpoint Blockade Treatment May Sensitize Hodgkin Lymphoma to Subsequent Therapy.
Carreau NA; Pail O; Armand P; Merryman R; Advani RH; Spinner MA; Herrera A; Chen R; Tomassetti S; Ramchandren R; Hamid MS; Assouline S; Santiago R; Wagner-Johnston N; Paul S; Svoboda J; Bair S; Barta S; Liu Y; Nathan S; Karmali R; Burkart M; Torka P; David K; Wei C; Lansigan F; Emery L; Persky D; Smith S; Godfrey J; Chavez J; Xia Y; Troxel AB; Diefenbach C
Oncologist; 2020 Oct; 25(10):878-885. PubMed ID: 32720734
[TBL] [Abstract][Full Text] [Related]
10. Emerging Therapies in Relapsed and Refractory Hodgkin Lymphoma: What Comes Next After Brentuximab Vedotin and PD-1 Inhibition?
Othman T; Herrera A; Mei M
Curr Hematol Malig Rep; 2021 Feb; 16(1):1-7. PubMed ID: 33409966
[TBL] [Abstract][Full Text] [Related]
11. Improved clinical outcome in a randomized phase II study of anti-PD-1 camrelizumab plus decitabine in relapsed/refractory Hodgkin lymphoma.
Liu Y; Wang C; Li X; Dong L; Yang Q; Chen M; Shi F; Brock M; Liu M; Mei Q; Liu J; Nie J; Han W
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33820822
[TBL] [Abstract][Full Text] [Related]
12. Outcomes and Toxicities of Programmed Death-1 (PD-1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Real-World, Multicenter Retrospective Analysis.
Bair SM; Strelec LE; Feldman TA; Ahmed G; Armand P; Shah NN; Singavi AN; Reddy N; Khan N; Andreadis C; Vu K; Huntington SF; Giri S; Ujjani C; Howlett C; Faheem M; Youngman MR; Nasta SD; Landsburg DJ; Schuster SJ; Svoboda J
Oncologist; 2019 Jul; 24(7):955-962. PubMed ID: 30568021
[TBL] [Abstract][Full Text] [Related]
13. Long-term results of brentuximab vedotin in relapsed and refractory Hodgkin lymphoma: multi-center real-life experience.
Özbalak M; Salihoğlu A; Soysal T; Karadoğan İ; Paydaş S; Özdemir E; Yıldız B; Karadurmuş N; Kaynar L; Yagci M; Özkocaman V; Topçuoğlu P; Özcan M; Birtaş E; Göker H; Ferhanoglu B
Ann Hematol; 2020 Feb; 99(2):301-307. PubMed ID: 31844933
[TBL] [Abstract][Full Text] [Related]
14. Body mass index is not associated with survival outcomes and immune-related adverse events in patients with Hodgkin lymphoma treated with the immune checkpoint inhibitor nivolumab.
De Filippi R; Morabito F; Santoro A; Tripepi G; D'Alò F; Rigacci L; Ricci F; Morelli E; Zinzani PL; Pinto A
J Transl Med; 2021 Dec; 19(1):489. PubMed ID: 34852840
[TBL] [Abstract][Full Text] [Related]
15. Nivolumab discontinuation and retreatment in patients with relapsed or refractory Hodgkin lymphoma.
Fedorova LV; Lepik KV; Mikhailova NB; Kondakova EV; Zalyalov YR; Baykov VV; Babenko EV; Kozlov AV; Moiseev IS; Afanasyev BV
Ann Hematol; 2021 Mar; 100(3):691-698. PubMed ID: 33528609
[TBL] [Abstract][Full Text] [Related]
16. Allogeneic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma: Real World Experience of a Single Center.
Kopińska A; Koclęga A; Wieczorkiewicz-Kabut A; Woźniczka K; Kata D; Włodarczyk M; Helbig G
Pathol Oncol Res; 2021; 27():1609867. PubMed ID: 34385892
[No Abstract] [Full Text] [Related]
17. Pixantrone, etoposide, bendamustine, rituximab (P[R]EBEN) as an effective salvage regimen for relapsed/refractory aggressive non-Hodgkin lymphoma-Polish Lymphoma Research Group real-life analysis.
Długosz-Danecka M; Hus I; Puła B; Jurczyszyn A; Chojnacki T; Blajer-Olszewska B; Drozd-Sokołowska J; Raźny M; Romejko-Jarosińska J; Taszner M; Jurczak W
Pharmacol Rep; 2019 Jun; 71(3):473-477. PubMed ID: 31003160
[TBL] [Abstract][Full Text] [Related]
18. Radiotherapy in combination with nivolumab for relapsed/refractory classical Hodgkin lymphoma: About two cases.
de Forceville L; Deau-Fischer B; Franchi P; Arsène-Henry A; Cassou Mounat T; Bouscary D; Kirova YM
Cancer Radiother; 2019 Jun; 23(3):232-239. PubMed ID: 31147173
[TBL] [Abstract][Full Text] [Related]
19. Kinetics and nadir of responses to immune checkpoint blockade by anti-PD1 in patients with classical Hodgkin lymphoma.
Dercle L; Ammari S; Seban RD; Schwartz LH; Houot R; Labaied N; Mokrane FZ; Lazarovici J; Danu A; Marabelle A; Ribrag V; Michot JM
Eur J Cancer; 2018 Mar; 91():136-144. PubMed ID: 29360605
[TBL] [Abstract][Full Text] [Related]
20.
Dercle L; Seban RD; Lazarovici J; Schwartz LH; Houot R; Ammari S; Danu A; Edeline V; Marabelle A; Ribrag V; Michot JM
J Nucl Med; 2018 Jan; 59(1):15-24. PubMed ID: 28596157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
